Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose steroids in children with stroke and unilateral focal cerebral arteriopathy
2022-500631-36-00Phase 3Authorised
- Sponsor
- Insel Gruppe
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised trial of methylprednisolone and prednisolone in focal cerebral arteriopathy (FCA) and brain infarction (2 arms), sponsored by Insel Gruppe. Planned start Jul 2024; status: authorised.
02
Drugs
methylprednisoloneprednisolone
03
Conditions
focal cerebral arteriopathy (FCA)brain infarction
Beyond the preview
Go deeper on 2022-500631-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500631-36-00.